The Checkmate-227 results surprised with an OS benefit for Opdivo plus Yervoy in first-line NSCLC and a miss for the Opdivo-chemotherapy combination. Bristol reported a solid quarter, with growth for IO, Eliquis.
A split decision had been expected in Bristol-Myers Squibb Co.’s Checkmate-227 study testing Opdivo combination therapy in first-line, non-squamous non-small cell lung cancer, but the win for Opdivo with low-dose Yervoy was a surprise – and could possibly open up a needed edge in the NSCLC setting for BMS.
The Princeton, NJ-based pharma unveiled top-line data from the Phase III Checkmate-227 after the markets closed on 24 July, hours...
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.
The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.
Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
